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Accelerated long-term forgetting in presymptomatic 
autosomal dominant Alzheimer’s disease: a cross-sectional 
study
Philip S J Weston, Jennifer M Nicholas, Susie M D Henley, Yuying Liang, Kirsty Macpherson, Elizabeth Donnachie, Jonathan M Schott, 
Martin N Rossor, Sebastian J Crutch, Christopher R Butler, Adam Z Zeman, Nick C Fox
Summary
Background Tests sensitive to presymptomatic changes in Alzheimer’s disease could be valuable for clinical trials. 
Accelerated long-term forgetting—during which memory impairment becomes apparent over longer periods than 
usually assessed, despite normal performance on standard cognitive testing—has been identified in other temporal 
lobe disorders. We assessed whether accelerated long-term forgetting is a feature of presymptomatic autosomal 
dominant (familial) Alzheimer’s disease, and whether there is an association between accelerated long-term forgetting 
and early subjective memory changes.
Methods This was a cross-sectional study at the Dementia Research Centre, University College London (London, UK). 
Participants were recruited from a cohort of autosomal dominant Alzheimer’s disease families already involved in 
research at University College London, and had to have a parent known to be affected by an autosomal dominant 
Alzheimer’s disease mutation, and not report any current symptoms of cognitive decline. Accelerated long-term 
forgetting of three tasks (list, story, and figure recall) was assessed by comparing 7-day recall with initial learning and 
30-min recall. 7-day recognition was also assessed. Subjective memory was assessed using the Everyday Memory 
Questionnaire. The primary outcome measure for each task was the proportion of material retained at 30 min that 
was recalled 7 days later (ie, 7-day recall divided by 30-min recall). We used linear regression to compare accelerated 
long-term forgetting scores between mutation carriers and non-carriers (adjusting for age, IQ, and test set) and, for 
mutation carriers, to assess whether there was an association between accelerated long-term forgetting and estimated 
years to symptom onset (EYO). Spearman’s correlation was used to examine the association between accelerated 
long-term forgetting and subjective memory scores.
Findings Between Feb 17, 2015 and March 30, 2016, we recruited 35 people. 21 participants were mutation carriers (mean 
EYO 7·2 years, SD 4·5). Across the three tasks, we detected no differences between carriers and non-carriers for initial 
learning or 30-min recall. The proportion of material recalled at 7 days was lower in carriers than non-carriers for list 
(estimated difference in mean for list recall –30·94 percentage points, 95% CI –45·16 to –16·73; p=0·0002), story (–20·10, 
–33·28 to –6·91; p=0·0048), and figure (–15·41, –26·88 to –3·93; p=0·012) recall. Accelerated long-term forgetting was 
greater in carriers nearer to their estimated age at onset (p≤0·01 for all three tests). Mutation carriers’ 7-day recognition 
memory was also lower across all tasks (list [mean difference –5·80, 95% CI –9·96 to –2·47; p<0·01], story [–6·84, –10·94 
to –3·37; p<0·01], and figure [–17·61, –27·68 to –7·72; p<0·01] recognition). Subjective memory scores were poorer in 
asymptomatic carriers compared with non-carriers (adjusted difference in means 7·88, 95% CI 1·36 to 14·41; p=0·016), 
and we found a correlation between accelerated long-term forgetting and subjective memory in mutation carriers.
Interpretation Accelerated long-term forgetting is an early presymptomatic feature of autosomal dominant 
Alzheimer’s disease, which appears to pre-date other amnestic deficits and might underpin subjective memory 
complaints in Alzheimer’s disease. Accelerated long-term forgetting testing might be useful in presymptomatic 
Alzheimer’s disease trials.
Funding MRC, NIHR, Alzheimer’s Research UK, Dementias Platform UK, Dunhill Medical Trust, ERUK, Great 
Western Research, Health Foundation, Patrick Berthoud Trust.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Pathological changes of Alzheimer’s disease develop 
years before clinical symptoms.1,2 The medial temporal 
lobe, which plays an important part in memory, is an 
early site of neurofibrillary tangle deposition and 
atrophy.3–5 Subtle cognitive impairment is likely to 
develop earlier than overt clinical symptoms, therefore 
cognitive measures sensitive to early changes would be 
valuable diagnostically and in presymptomatic trials.
Autosomal dominant (familial) Alzheimer’s disease, 
due to mutations in presenilin 1 (PSEN1), presenilin 2 
(PSEN2), or amyloid precursor protein (APP) genes, 
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shares many features, both pathophysiologically and 
clinically, with the much more common sporadic form of 
the disease.6 Autosomal dominant Alzheimer’s disease 
mutation carriers have relatively predictable ages at 
symptom onset based on family history,7 and therefore 
provide an opportunity to study presymptomatic 
cognitive change where time to symptom onset can be 
estimated.
Deficits in episodic memory are one of the earliest 
detectable cognitive abnormalities in Alzheimer’s 
disease.8–10 However, there is a substantial delay between 
pathological change and measurable cognitive decline.2
Accelerated long-term forgetting is a form of memory 
impairment that has been described in patients with 
temporal lobe epilesy.11,12 It refers to a process whereby 
new material appears to be encoded and retained 
normally over periods of up to 30 min—consistent with 
normal performance on standard memory tests—but is 
then forgotten at an abormally rapid rate over the 
following hours to weeks. Accelerated long-term 
forgetting might represent disruption in memory 
consolidation,13 which refers to gradual post-acquisition 
stabilisation of long-term memories, with the medial 
temporal lobe known to play an important part.14
Accelerated long-term forgetting was associated with 
subjective cognitive concerns in patients with epilepsy.11,12 
Such concerns might also be a preclinical harbinger of 
cognitive decline in Alzheimer’s disease.15–18
Accelerated long-term forgetting has recently been 
assessed in a mouse model of presymptomatic autosomal 
dominant Alzheimer’s disease.19 Genetically modified 
mice had abnormal memory retention after 7 days, 
despite normal learning and retention over shorter 
intervals.
We hypothesised that accelerated long-term forgetting 
would also be a feature of presymptomatic autosomal 
dominant Alzheimer’s disease in human beings, with 
mutation carriers forgetting more material over 7 days 
Research in context
Evidence before this study
Accelerated long-term forgetting is a feature of temporal lobe 
epilepsy. We investigated whether accelerated long-term 
forgetting had been assessed in early Alzheimer’s disease by 
searching PubMed for articles published between Jan 1, 1980, 
and April 11, 2016, with the terms “Alzheimer’s disease” AND 
“long-term forgetting” OR “accelerated forgetting”. No articles 
that reported accelerated long-term forgetting in 
presymptomatic Alzheimer’s disease were found. We then did a 
second PubMed search using the terms “Alzheimer’s disease” 
AND “familial” OR “autosomal dominant” AND 
“presymptomatic” OR “preclinical” AND “cognitive” OR 
“memory” to identify studies of early cognitive change in 
autosomal dominant Alzheimer’s disease. No langauge 
restrictions were used in either of the searches. The general 
pattern reported in these studies was of episodic memory 
decline evident up to 2–3 years before the expected onset of 
symptomatic disease, although one longitudinal study showed 
measurable decline only after the time of estimated onset. No 
studies assessing episodic memory had a retention interval of 
longer than 30 min. Visual short-term memory binding and 
dual task performance also declined in mutation carriers around 
2 years before symptom onset. No studies were identified that 
showed earlier presymptomatic cognitive decline.
Added value of this study
To our knowledge, this study presents the first assessment of 
long-term forgetting in asymptomatic individuals who perform 
normally on conventional memory tests but have known 
Alzheimer’s pathology. We found that differences in accelerated 
long-term forgetting were detectable in individuals who were 
on average 7 years away from predicted onset of symptomatic 
disease. We found that long-term retention of both verbal and 
visual material was affected, with impairment of recall and 
recognition. Accelerated long-term forgetting appears to 
pre-date other previously identified early Alzheimer’s 
disease-related cognitive changes. Subtle increases in subjective 
cognitive concerns are also present several years before 
expected symptom onset.
Implications of all the available evidence
Our results add to existing evidence that episodic memory is 
impaired before symptom onset in individuals with Alzheimer’s 
disease pathology. However, by assessing memory retention 
over a longer interval than is conventionally used, it is possible 
to detect verbal and visual memory deficits earlier than 
previously thought. Accelerated long-term forgetting appears 
to be one of the earliest detectable features of Alzheimer’s 
disease-related cognitive decline. The results of this study 
extend our understanding of the temporal sequence of memory 
decline in Alzheimer’s disease; it was previously possible to 
separate healthy ageing from Alzheimer’s disease dementia and 
mild cognitive impairment by testing encoding and short 
interval retention. Assessment of accelerated long-term 
forgetting appears to provide a means of discriminating healthy 
ageing from asymptomatic individuals in the presymptomatic 
phase of Alzheimer’s disease. Our findings of early, subtle 
subjective memory changes before overt symptoms in 
individuals with known Alzheimer’s disease pathology, support 
research suggesting that subjective changes are predictive of 
future decline. The potential association between subjective 
memory change and accelerated long-term forgetting is 
consistent with previous epilepsy studies and, if confirmed, 
might explain the mechanism of early subjective change in 
Alzheimer’s disease. Future work is required to define more 
precisely when deficits appear relative to actual symptom onset 
and to determine the use of accelerated long-term forgetting 
assessment in presymptomatic Alzheimer’s disease trials.
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compared with non-carriers, despite similar learning 
and short interval (30 min) retention. Additionally, we 
investigated whether accelerated long-term forgetting is 
associated with subjective cognitive concerns.
Methods
Study design and participants
We did a cross-sectional study at the Dementia Research 
Centre, University College London (London, UK). 
Participants were recruited from families who were 
already actively involved (ie, consented to inclusion) in a 
long-running longitudinal study of autosomal dominant 
Alzheimer’s disease at University College London. 
All participants, by having an affected parent, were at 
50% risk of carrying a pathogenic autosomal dominant 
Alzheimer’s disease mutation.6 Participants were also 
required to be asymptomatic, with neither they nor their 
informant reporting progressive cognitive symptoms. 
A further inclusion criterion was being aged older than 
18 years. Participants were excluded from the study 
if they had substantial co-existing neurological or 
psychiatric disease. The study was approved by the local 
Research Ethics Committee and all participants provided 
written informed consent.
Procedures
Genetic testing was done to establish mutation status 
and results were provided only to statisticians, ensuring 
that participants and clinicians assessing them remained 
blind to genetic status. All individuals identified a close 
informant who was interviewed separately to gain a 
collateral history. Estimated years to symptom onset were 
calculated by subtracting the participant’s age at testing 
from the age at which their affected parent first developed 
progressive cognitive symptoms.
Participants underwent neurological examination and 
assessment using the mini mental state examination and 
the Clinical Dementia Rating scale,20 which incorporates 
information from both participant and informant 
on day-to-day cognition. Neuropsychological testing 
included measures of general intellectual functioning 
(Wechsler Abbreviated Scale of Intelligence [WASI]),21 
verbal and visual recognition memory (Recognition 
Memory Test for words and faces),22 and paired associate 
learning (Camden paired associate learning test).23 
Depression and anxiety were assessed using the Hospital 
Anxiety and Depression Scale (HADS).24 Subjective 
memory was assessed using the Everyday Memory 
Questionnaire (EMQ),25 scored between 0 and 90, with 
higher scores indicating greater concerns.
Long-term forgetting was assessed using test materials 
from the Adult Memory and Information Processing 
Battery.26 Assesment was 1–3 months after background 
clinical data collection. This 2-month window was 
allowed because of practical considerations that meant it 
was not always possible for every participant to return for 
assesment after exactly the same interval. A minimum 
1-month gap was left between neuropsychological testing 
and long-term forgetting assessment so that participants 
did not confuse material from the two types of test. 
Participants were assessed on three tests: learning and 
recall of a 15-item word list, a short story, and a complex 
visual figure. For the word list, participants had to learn 
the material to a minimum required accuracy of 80% over 
a minimum of four and maximum of ten trials. For the 
story, the minimum required accuracy was 80%, over a 
minimum of two and maximum of ten trials. For the 
figure, participants were first asked to copy the figure as 
accurately as possible on to a separate piece of paper; the 
figure and copy were then removed and participants 
were asked to draw the figure again from memory. 
Participants were then tested on free recall of the word 
list, story, and figure 30 min after presentation of the last 
learning trial for each test. All three tests (list, story, and 
figure) were marked by the same assessor (PSJW) using 
validated marking criteria.26
There were two versions of each test. Participants were 
randomly assigned to either set one or set two (a random 
number was generated [either 1 or 2] before testing each 
participant, which was then used to decide the set), 
except for families in which two members were 
participating, in which case the second participant in a 
family was always assessed on a different version from 
the first participant. Participants were requested not to 
discuss the tests with other participants.
Following assessment, participants were given an 
envelope (appendix), which they were asked not to open 
until told to do so during a telephone call 7 days later. 
Participants were not told that the memory tests would be 
repeated. At the 7-day telephone call, participants’ free 
recall of the test materials was reassessed. For the figure, 
they were asked to draw the figure on a blank piece of 
paper included in the envelope, and for the verbal tests 
recall was done orally. Forced-choice recognition memory 
was then assessed. For the word list, participants were read 
15 semantically unrelated word pairs, and asked to identify 
which of each pair was in the original list. A similar 
three-alternative forced-choice response procedure was 
done for 12 separate aspects of the story. For the figure, 
participants were asked to view a sheet (contained in a 
separate envelope) showing four sets of three similar 
Mutation carriers (n=21) Non-carriers (n=14)
Sex
Male 11 (52%) 6 (43%)
Female 10 (48%) 8 (57%)
Age (years) 38·0 (5·9) 39·2 (7·9)
Estimated years to 
symptom onset
7·2 (4·5) NA
Years of education 13·8 (2·5) 14·4 (2·2)
Data are n (%) or mean (SD). NA=not applicable.
Table 1: Participant characteristics
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illustrations and were asked to mark which of each set of 
three exactly matched part of the figure. Figure assessments 
were returned in a stamped addressed envelope.
Outcomes
The primary outcome measure of interest was the 
proportion of material (list, story, and figure) retained at 
30 min that was recalled 7 days later (ie, 7-day recall divided 
by 30-min recall). This approach, used in previous studies 
in patients with epilepsy,27 allows comparison of group 
differences at 7 days, adjusting within each individual for 
short interval (30-min) forgetting. Secondary outcomes 
were 7-day recall and recognition scores for each of the 
three tasks. The only other secondary outcome was 
subjective memory score, although this was separate from 
the long-term forgetting analysis.
Statistical analysis
Scores on standard cognitive tests, HADS, EMQ, and 
accelerated long-term forgetting initial learning (score on 
the final learning trial), number of trials to criterion, 
30-min recall, 7-day recall, 7-day score divided by 30-min 
score, and 7-day recognition were compared between 
mutation carriers and non-carriers using linear regression 
with robust SEs to account for clustering of participants 
within families. Linear regression was used to examine 
the association between 7-day score divided by 30-min 
score on each accelerated long-term forgetting test and 
estimated years to symptom onset (EYO), with robust SEs 
to account for clustering of participants within families. 
If plots of model residuals indicated a departure from 
the assumption of normal distribution with constant 
variance, statistical inference was based on non-parametric 
Mutation carriers Non-carriers p value Difference in mean 95% CI
Learning
List learning trials 5·0 (4·0–6·0) 4·0 (4·0–6·0) >0·05 −0·06 −1·01 to 0·97
Story learning trials 3·0 (2·0–3·0) 2·0 (2·0–3·0) >0·05 0·07 −0·50 to 0·82
List learning score 80·0% (80·0–86·7) 86·7% (80·0–93·3) >0·05 −1·77 −7·01 to 2·49
Story learning score 87·5% (83·3–91·1) 90·5% (87·5–94·6) 0·67 −0·60 −3·50 to 2·30
Figure learning score 100·0% (97·4–100·0) 100·0% (99·3–100·0) >0·05 6·39 −4·00 to 15·21
30-min retention
List 30-min recall 80·0% (73·3–80·0) 80·0% (73·3–86·7) 0·85 0·66 −6·52 to 7·84
Story 30-min recall 83·3% (80·0–87·5) 87·9% (80·4–91·1) 0·76 −0·74 −5·77 to 4·29
Figure 30-min recall 92·5% (72·4−97·4) 88·4% (72·4−96·7)  0·34 5·72 −6·55 to 17·98
7-day retention (seconday outcomes)
7-day list recall 26·7% (20·0–46·7) 56·7% (46·7–66·7) 0·0021 −24·55 −39·01 to −10·10
7-day story recall 56·7% (50·0–68·3) 79·3% (71·4–83·9) 0·0031 −17·97 −29·06 to −6·88
7-day figure recall 59·2% (48·8–73·7) 74·3% (62·5–83·2) 0·22 −8·67 −22·91 to 5·57
7-day list recognition 93·3% (86·7–100·0) 100·0% (100·0–100·0) <0·01 −5·80 −9·96 to −2·47
7-day story recognition 91·7% (91·7–100·0) 100·0% (100·0–100·0) <0·01 −6·84 −10·94 to −3·37
7-day figure recognition 75·0% (75·0–100·0) 100·0% (100·0–100·0) <0·01 −17·61 −27·68 to −7·72
7-day retention (primary outcome)
List 7-day recall divided by 30-min recall 36·4 (30·0–58·3) 71·8 (55·6–81·8) 0·0002 −30·94 −45·16 to −16·73
Story 7-day recall divided by 30-min recall 66·7 (58·8–81·3) 92·2 (81·1–95·7) 0·0048 −20·10 −33·28 to −6·91
Figure 7-day recall divided by 30-min recall 70·3 (63·2–82·1) 87·6 (76·9–96·4) 0·012 −15·41 −26·88 to −3·93
Data are uncorrected group medians (IQR). Exact p values are shown for variables that satisfied the assumptions of the linear regression model. For other variables, 
parametric assumptions were not met and therefore p<0·05 or p>0·05 and p<0·01 or p>0·01 was inferred from bootstrapped 95% and 99% CIs. Differences in means, 
95% CIs, and p values are adjusted for age, intelligence quotient (Wechsler Abbreviated Scale of Intelligence total score), and test set. Robust standard errors accounted for 
clustering of participants within families. Secondary outcome measures for each of the three tests were 7-day recall and recognition scores, with the primary outcome 
measure being 7-day recall divided by 30-min recall. For the list and story, learning score refers to the score from the final learning trial.
Table 3: Long-term forgetting assessment results
Mutation carriers Non-carriers p value
HADS anxiety score (out of 21) 6·0 (3·0–9·0) 4·5 (4·0–7·0) 0·47
HADS depression score (out of 21) 2·0 (0·0–2·0) 1·0 (0·0–2·0) 0·59
Mini mental state examination (out of 30) 29·0 (29·0–30·0) 29·5 (29·0–30·0) >0·05
WASI verbal IQ 106 (91–108) 103 (95–103) 0·37
WASI performance IQ 104 (100–116) 119 (106–121) 0·03
Recognition Memory Test words (out of 50) 49·0 (49·0–50·0) 48·0 (46·0–50·0) <0·05
Recognition Memory Test faces (out of 50) 45·0 (43·0–48·0) 45·5 (44·0–47·0) >0·05
Camden paired associate learning (out of 24) 19·0 (16·0–22·0) 19·0 (17·0–22·0) >0·05
Data are median (IQR). p values are shown for variables that satisfied the assumptions of the linear regression model. 
For other variables, parametric assumptions were not met and therefore p<0·05 or p>0·05 was inferred from 
bootstrapped 95% CIs. For HADS anxiety, HADS depression, mini mental state examination, Recognition Memory Test 
faces, Recognition Memory Test words, and Camden paired associate learning, p values reflect group differences after 
adjusting for age (years) and IQ (WASI total score). Analysis of WASI performance IQ and WASI verbal IQ was 
unadjusted, as these measures were corrected for age. HADS=Hospital Anxiety and Depression Scale. WASI=Wechsler 
Abbreviated Scale of Intelligence.
Table 2: Mood assessment and standard tests of intelligence and memory results
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bias-corrected and accelerated 95% CIs and 99% CIs 
from 10 000 bootstrap replications clustered on family.
Comparison of HADS, mini mental state examination, 
Recognition Memory Test faces, Recognition Memory 
Test words, Camden paired associated learning test, and 
EMQ was adjusted for age and intelligence quotient (IQ; 
WASI total). Comparison of WASI performance IQ and 
WASI verbal IQ was unadjusted, as these measures were 
corrected for age. Comparison of groups with regards to 
accelerated long-term forgetting scores was adjusted for 
age, IQ, and test set.
Non-parametric receiver operating characteristic (ROC) 
curves were used to quantify the ability of the 7-day score 
divided by the 30-min score on each of the accelerated 
long-term forgetting tests to discriminate between 
carriers and non-carriers. Areas under the curves (AUCs) 
were calculated and cutoffs, specificities, and sensitivities 
reported.
The association between EMQ and 7-day score divided 
by 30-min score on each accelerated long-term forgetting 
test was assessed using the non-parametric Spearman 
correlation coefficient, with inference based on 
non-parametric bias-corrected and accelerated 95% and 
99% CIs from 10 000 bootstrap replications clustered on 
family. For analyses involving EMQ, only participants 
who were unaware of their mutation status were 
included, as knowledge of status might bias an 
individual’s perception of their memory.
Results were interpreted taking into consideration that 
a Bonferroni correction for use of three accelerated 
long-term forgetting tests (list, story, figure) would 
require p<0·017 (ie, 0·05 divided by 3) for formal 
statistical significance.
For the four figure recall and recognition assessment 
documents that were not returned, these data were 
assumed to be missing entirely at random. Data were not 
imputed for missing cases. 
All statisitcal analyses were done using Stata version 
14.0 or later.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
We recruited 35 asymptomatic individuals from 
19 autosomal dominant Alzheimer’s disease families 
between Feb 17, 2015, and March 30, 2016. Nine participants 
(five mutation-positive, four mutation-negative) had 
previously chosen to have clinical predictive genetic 
testing, and so were aware of their genetic status. 
21 (60%) of 35 participants were mutation carriers. All 
participants scored 0 for both global Clinical Dementia 
Rating scale and Clinical Dementia Rating scale Sum of 
Boxes. Carriers and non-carriers were well matched for 
age, sex, and years in education (table 1). All participants 
were right-handed. Carriers were on average 7·2 years 
(SD 4·5) from estimated symptom onset. Scores for 
mutation carriers and non-carriers did not differ for mood 
and for most conventional tests of memory and global 
intelligence, although carriers had higher recognition 
memory for words (adjusted estimated difference in 
means 2·2, 95% CI 1·0–3·6; p<0·01 and non-carriers had 
slightly higher performance IQ (8·2, 1·0–15·4; p=0·027; 
table 2).
All participants learned the word list and story to the 
required 80% accuracy within the allowed number of 
trials. Across all three accelerated long-term forgetting 
tests, adjusting for age, IQ, and test set, and accounting 
Figure 1: Long-term forgetting assessments
Scores for (A) word list, (B) story, and (C) figure were adjusted for age, 
intelligence quotient (WASI total score), and test set. Robust SEs accounted for 
within-family clustering. WASI=Wechsler Abbreviated Scale of Intelligence.
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for clustering within families, the ability of mutation 
carriers to learn the material did not differ from 
non-carriers, both in terms of initial score and in the 
number of learning trials (table 3). Recall score at 30 min 
for all three tasks did not differ between groups (table 3, 
figure 1). All participants completed all assessments. 
However, four participants failed to return the 7-day figure 
recall and recognition assessment documents, so these 
could not be included in the analysis of these measures.
For 7-day recall scores divided by 30-min recall scores, 
mutation carriers did worse than non-carriers for list 
(adjusted difference in means –30·94 percentage points, 
95% CI –45·16 to –16·73; p=0·0002), story (–20·10, 
–33·28 to –6·91; p=0·0048) and figure (–15·41, –26·88 to 
–3·93; p=0·012) recall.
The poorer retention of material at 7 days in mutation 
carriers was also seen in lower mean 7-day recall scores for 
list and story categories than in non-carriers, but not for 
figure (table 3). Mutation carriers also did worse than 
non-carriers on 7-day list, story, and figure recognition 
(table 3).
ROC analysis for discrimination between mutation 
carriers and non-carriers for 7-day score divided by 
30-min score revealed an AUC of 0·86 (95% CI 
0·66–0·95) for list, 0·84 (0·62–0·96) for story, and 0·79 
(0·53–0·93) for figure scores (figure 2). A cutoff of less 
than 60% on list long-term retention gave 76% sensitivity 
and 71% specificity for mutation carriers versus non-
carriers. A cutoff of less than 88% for story recall gave 
90% sensitivity and 71% specificity. A cutoff of less than 
75% for figure recall gave 79% sensitivity and 
67% specificity.
There was an association between long-term forgetting 
and EYO for list, story, and figure scores, with the severity 
of accelerated long-term forgetting increasing with 
proximity to predicted symptom onset (figure 3).
Neither mutation carriers (median 18·5 [IQR 12–23] 
of 90 maximum) or non-carriers (12·5 [8–15] of 
maximum of 90) had high EMQ scores (having excluded 
participants who knew their genetic status). However, 
mutation carriers had more subjective memory 
concerns than did non-carriers (adjusted difference in 
means 7·88, 95% CI 1·36–14·41; p=0·016) (figure 4). In 
mutation carriers, an association existed between higher 
EMQ and poorer long-term retention (7-day recall score 
divided by 30-min recall score), which reached statistical 
significance for both list and story, but not for figure 
(figure 5). There was no evidence of an association 
between EMQ score and performance on standard 
cognitive tests.
Discussion
We found that accelerated long-term forgetting was 
a feature of presymptomatic autosomal dominant 
Alzheimer’s disease in a group of individuals who were 
on average 7 years from estimated symptom onset. 
Despite similar learning and ability to recall over a 
short interval, reassessment 7 days later showed that 
Figure 3: Scatter plots for EYO against long-term recall scores in mutation carriers
(A) Word list, (B) story, and (C) figure. EYO=estimated years to onset.
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Figure 2: ROC curves for accelerated long-term forgetting testing as a discriminator between presymptomatic mutation carriers and non-carriers
ROC curves are shown for 7-day score divided by 30-min score for (A) list, (B) story, and (C) figure scores. Red dots indicate the point on each curve for the proposed optimum cutoffs. 
ROC=receiver operating characteristic.
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presymptomatic mutation carriers had forgotten more 
than had non-carriers. This finding was consistent for 
recall and recognition memory, and for verbal and 
non-verbal material. Among mutation carriers, severity 
of accelerated long-term forgetting increased with 
proximity to estimated symptom onset.
By contrast, mutation carriers showed no impairment 
in performance on conventional memory tests, which 
included both recognition memory for words and faces 
and paired associate learning. This finding suggests that 
differences in long-term forgetting are unlikely to be due 
to problems with encoding or early retention, but rather 
are caused by impairment of long-term memory 
consolidation. Although impairment of episodic 
memory is recognised as a central component of the 
Alzheimer’s disease phenotype, relatively little is known 
about how long-term consolidation of memory is 
affected. Some studies have investigated potential 
consolidation deficits in early Alzheimer’s disease,28 but 
it is difficult to measure long-term retention of memory 
reliably and compare a disease group with controls, 
unless the groups are equal for initial encoding and 
short interval retention, which in these studies was not 
the case.29,30 By recruiting a presymptomatic Alzheimer’s 
disease cohort, and testing retention over a longer period 
than in standard neuropsychological assessment, we 
showed that impairment of long-term retention is an 
early amnestic feature of Alzheimer’s disease, and might 
be one of the earliest features of Alzheimer’s 
disease-related cognitive decline.
A previous study8 of autosomal dominant Alzheimer’s 
disease tested recognition memory over a more 
conventional interval of about 5 min and identified 
presymptomatic memory changes, but only 1–2 years 
before symptom onset. Other studies31–33 of pre-
symptomatic carriers (from the PSEN1 Colombian 
kindred) showed reduced cognitive performance in 
several domains, including visual short-term memory 
binding, dual task performance, and lexical-semantic 
processing; however, participants were closer to expected 
symptom onset than were those in our study. Another 
study34 of the same cohort found that earlier decline 
could be identified by using a composite score comprising 
multiple tests. A similar composite cognitive test 
approach, which included paired associate learning, 
delayed recall, naming, and digit-symbol substitution 
Figure 4: Box and whisker plots, with individual data points superimposed 
for EMQ score
Boxes show 25–75th percentile, lines show median, and whiskers show range of 
EMQ scores. The score is out of a maximum of 90, with higher scores indicating 
greater subjective cognitive concerns. Only individuals who did not know their 
genetic status were included. EMQ=Everyday Memory Questionnaire.
Figure 5: EMQ score against long-term recall score in mutation carriers
Comparison of EMQ score with long-term forgetting score (7-day recall divided by 30-min recall) for (A) word list, (B) story, and (C) figure. Only the 16 mutation 
carriers who did not know their genetic status were included. EMQ=Everyday Memory Questionnaire.
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(an assessment of short-term memory and processing 
speed) identified decline in individuals in the late stage 
of presymptomatic sporadic Alzheimer’s disease.35
We also found group differences in recognition 
memory at 7 days. Impaired recognition, which implies a 
so-called storage deficit rather than an isolated retrieval 
deficit, is consistent with pathology primarily affecting 
the medial temporal lobe,36 a brain region affected early 
in Alzheimer’s disease.
ROC analysis indicated that accelerated long-term 
forgetting assessments might provide a means of 
discriminating between presymptomatic Alzheimer’s 
disease and healthy ageing, with discriminatory power 
being stronger for verbal tests (list and story) than for the 
figure test. However, the sample size of the current study 
limits the precision with which AUCs can be estimated. 
Moreover, specificity values for our proposed cutoffs are 
suboptimal, and further work is needed to determine the 
most suitable cutoffs.
Our findings advance existing understanding of the 
stages of memory decline in Alzheimer’s disease. 
Previous studies37 have reported discrimination of 
Alzheimer’s disease-dementia from Alzheimer’s 
disease mild cognitive impairment based on initial 
encoding of memory, which has been found to be 
impaired in the dementia stage but not in mild cognitive 
impairment. Similarly, Alzheimer’s disease mild 
cognitive impairment can be separated from 
presymptomatic disease and healthy ageing based on 
short-term retention (eg, over 30 min), which is 
impaired only in Alzheimer’s disease mild cognitive 
impairment. Our results suggest that incorporating 
tests of long-term (eg, 7-day) retention might allow 
individuals with presymptomatic Alzheimer’s disease 
(but without conventional deficits) to be distinguished 
from healthy ageing (table 4).
Other than accelerated long-term forgetting, the only 
group difference where carriers performed worse than 
non-carriers on cognitive testing was for performance 
IQ. This finding is consistent with previous findings in 
autosomal dominant Alzheimer’s disease that, along 
with episodic memory, reduced performance IQ is one of 
the earliest cognitive changes.8 However, the proportional 
difference in performance IQ between groups was much 
smaller than for accelerated long-term forgetting. As we 
adjusted for WASI score in all regression analyses, it is 
unlikely that the difference in performance IQ influenced 
the main study findings.
Despite reporting no overall concerns about their 
memory and being unaware of their genetic status, we 
found that presymptomatic mutation carriers had worse 
subjective memory scores than non-carriers, which 
supports emerging evidence that subtle subjective 
cognitive concerns might be a harbinger of Alzheimer’s 
disease-related cognitive decline.15–18 In mutation carriers, 
greater subjective cognitive concerns were associated with 
accelerated long-term forgetting for two of the three 
components (list and story). This association is consistent 
with findings from previous epilepsy studies,11,12,38 although 
a study39 assessing a combination of different neurological 
diagnoses did not identify a relationship. Early subjective 
memory concerns in Alzheimer’s disease, in the absence 
of conventional deficits, might reflect accelerated forgetting 
and impairments in long-term recall.
Our findings have parallels with a study of APP 
transgenic mice.19 Very young mice that had normal 
learning of a spatial navigation task and normal retention 
over a short interval had significantly reduced retention 
compared with wild-type mice when retested 7 days later. 
Furthermore, the deficit in long-term retention could 
potentially be rescued by anti-amyloid β immunotherapy.19 
These results, alongside our findings, suggest that 
assessment of long-term forgetting in human beings 
might be useful as a marker of treatment response in 
presymptomatic therapeutic trials.
Our study has several limitations. First, the sample 
size is small, primarily because of the relative rarity of 
autosomal dominant Alzheimer’s disease. Replication 
of our findings in both familial and sporadic 
presymptomatic Alzheimer’s disease cohorts is therefore 
important. Although participants were asked not to 
discuss the testing following the initial learning and 
30-min recall task, some individuals could have 
rehearsed the material during the intervening period, 
which is an inherent difficulty with accelerated long-term 
forgetting testing.29 However, when asked following the 
7-day testing, all participants said that they had not 
rehearsed. Rehearsal might be more difficult to avoid in 
a trial with repeated measures, which could reduce test 
sensitivity. Therefore, it is important to identify methods 
to reduce the potential for rehearsal, such as embedding 
the accelerated long-term forgetting assessment material 
among other unrelated cognitive tests or making use of 
recognition tests for material that is difficult to 
rehearse.40,41 We found a ceiling effect on the 7-day 
recognition testing, which could be reduced in future 
studies by using more demanding tests (eg, paired 
associate learning).42
We did not assess participants’ sleep between initial 
learning and 7-day testing. Sleep is thought to play an 
Memory encoding Early retention Long-term retention
Alzheimer’s disease dementia Reduced Reduced Reduced
Mild cognitive impairment Normal/unchanged Reduced Reduced
Presymptomatic Alzheimer’s 
disease
Normal/unchanged Normal/unchanged Reduced
Healthy ageing Normal/unchanged Normal/unchanged Normal/unchanged
Previous studies have established differences in memory function between Alzheimer’s disease dementia, Alzheimer’s 
disease mild cognitive impairment, and healthy ageing, based on tests of memory encoding and retention over a short 
interval. The results of our study allow us to propose a third column, for long-term retention, which shows impairment 
several years before onset of noticeable symptoms.
Table 4: Proposed stages of progressive memory impairment in Alzheimer’s disease, relative to healthy 
ageing
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important part in memory consolidation.43 However, a 
previous epilepsy study found sleep quality to have no 
direct effect on accelerated long-term forgetting,44 and we 
found no group difference in mood, which correlates 
with sleep.45 7-day assessment was done remotely, which 
allows other sources of variability, including the 
surrounding environment, to add noise. Nevertheless, 
we detected group differences in retention at 7 days, 
suggesting robust effects.
We used parental age at onset to estimate when an 
individual would develop Alzheimer’s disease symptoms. 
Although parental age at onset correlates closely with 
actual age at onset, it is a proxy measure,7 and only with 
longer-term follow-up can actual ages at symptom onset 
be confirmed.
In summary, we showed that accelerated long-term 
forgetting is present in autosomal dominant Alzheimer’s 
disease mutation carriers, who were on average 7 years 
from predicted symptom onset, and thus might be a very 
early feature of Alzheimer’s disease-related cognitive 
decline. Subtle increased subjective cognitive concerns 
also appear to be a presymptomatic feature of autosomal 
dominant Alzheimer’s disease, which could be 
underpinned by accelerated long-term forgetting. Studies 
of accelerated long-term forgetting might provide 
insights into very early cognitive impairments in 
Alzheimer’s disease, and accelerated long-term forgetting 
might be useful as part of inclusion criteria or as an 
outcome measure in presymptomatic Alzheimer’s 
disease trials.
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